The Tres Cantos Open Lab Foundation has welcomed a further £5m of funding from global healthcare company GlaxoSmithKline (GSK), to continue its work to fight the diseases of the developing world.
This funding builds on the initial £5m of seed funding with which GSK established the Tres Cantos Open Lab Foundation – an independent, not-for-profit organisation – in 2010.
The Tres Cantos Open Lab Foundation aims to fund and otherwise support research in to diseases of the developing world, including malaria and tuberculosis, at, or in collaboration with, GSK’s Tres Cantos Medicines Development Campus in Spain. It also supports the dissemination of results from this research, to encourage other scientific institutions to build on this work and thus accelerate the discovery of new medicines.
Professor Sir Leszek Borysiewicz, Trustee and Chair of the Tres Cantos Open Lab Foundation and Vice-Chancellor of the University of Cambridge, said “In the open lab at Tres Cantos we are able to put together the elements needed to start the discovery of new medicines for diseases of the developing world, which include funding, knowledge, expertise and technology. The additional GSK grant means we can continue to support the next wave of open lab researchers.”
“The Tres Cantos open lab is a bold concept enabling external researchers from different public and private research groups to access the resources and facilities at the specialist pharmaceutical research centre and collaborate with GSK scientists. This multiplies the effectiveness of any independent research they might conduct by pooling knowledge, thinking and resources,” he added.
To date, the Tres Cantos Open Lab Foundation has committed funds for 13 projects in the open lab at Tres Cantos. The funded research projects are addressing unmet needs in malaria, TB and Kinetoplastid diseases.
About the Tres Cantos Open Lab Foundation
The Tres Cantos Open Lab Foundation is an independent not-for-profit organisation supporting scientists, academics and institutions to develop and advance ideas that could lead to new medicines to treat diseases of the developing world. The Foundation provides funding and support for collaborative research projects undertaken by visiting scientists working in the open lab at GSK’s Tres Cantos Medicines Development Campus near Madrid in Spain. Proposals for projects can be submitted via the website, and are reviewed by the Foundation’s Governing Board and Trustees.